Non-Muscle Invasive Bladder Cancer (includes Ta, T1, CIS tumors) , Ta or CIS: Can include both low and non-muscle invasive, high grade non-muscle invasive bladder cancer (NMIBC), or Carcinoma in Situ (CIS)

Chemotherapy

Intravesical chemotherapy

• People with low-grade, intermediate risk bladder cancer that has come back but has not spread into the bladder wall.

• ZUSDURI goes into your bladder as a liquid.
• Inside the bladder, it warms up to body temperature and turns into a gel.
• The gel slowly releases medicine (mitomycin) over about 5 hours (sometimes up to 24 hours).
• The medicine leaves your body when you urinate.
• Important: Avoid urine touching your skin for at least 24 hours after treatment. Follow your doctor’s safety instructions carefully. Follow the patient instructions available on the website.

• People with low-grade, intermediate risk bladder cancer that has come back but has not spread into the bladder wall.

• The liquid medicine is put into your bladder through a thin tube called a catheter.
• The medicine turns into a gel inside your bladder, so it stays there longer (average of 5 hours but some reports of up to 24 hours).
• You will usually go home the same day after treatment.

• Pain or burning when you urinate
• Urinary tract infection
• Blood in urine
• Low red or white blood cell counts
• Changes in blood tests (kidney or liver)
• High potassium levels in blood

• It is not given with other treatments.
• ZUSDURI is typically given in an outpatient clinic or a doctor’s office by a trained healthcare professional. Patients can go home the same day.
• You do not need to be put to sleep to receive this
• ZUSDURI should not be used in patients with a bladder tear or in patients with allergy to mitomycin.